Abcellera Biologics Inc ABCL

$11.93 +0.13 (1.10%)

Valuation

Market cap
3,618,010,000
Revenue TTM
$75,130,000
Net income TTM
$-146,410,000
PE ratio
0.00
Forward PE
—
Profit margin
-194.88%
Debt to equity
0.00

Trading

Volume
3,136,800
Avg volume
7,039,568
Day's range
$11.75 – $12.28
Shares out
306,611,000
Stochastic %K
14%
Beta
1.41
Analysts
Strong Sell
Price target
$16.82

Price

Company profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...

Show more

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Phone
604 559 9005
Website
https://www.abcellera.com
Address
150 W 4th Avenue, Vancouver, Canada

Latest news

Stocktwits

VolumeSpreadAnalysis Oct 20, 1:06 PM
$ABCL Price: $11.93 Volume: Average or below Catalyst: Recent partnership/licensing updates around its Biofoundry platform keeping speculative interest alive. Resistance: $13.50 Support: $10.75 Bull case: Reclaiming $13.50 on rising volume could spark a squeeze toward the mid-teens. Bear case: A breakdown below $10.75 on heavy volume opens the door to retest single-digit lows. What I'm watching: Need volume to confirm any move before trusting a breakout or breakdown. Note: I’m not a financial advisor or a market predictor, and I don’t offer any premium subscriptions or paid services. Feel free to check out the link in my bio: @VolumeSpreadAnalysis
0 replies
tranq19 Oct 20, 7:45 AM
$ABCL executive order yesterday can’t hurt the discussions They’re currently having with the FDA
0 replies
Stocktradesmoon Oct 20, 3:15 AM
$ABCL 👀🏅🤯😮 WAVE 5 PT $21.69 🔥 Beautiful Chart !!! Nice Consolidation ✅ Huge Buys ✅ Ready for the NEXT LEG UP!!! Let’s F******* GOOOOO!!!🔥
0 replies
Stocktradesmoon Oct 20, 2:54 AM
$ABCL Agree! @XxZeeMoneyxX we get some positive news 🗞️ Pre-Market TODAY? Trap the bears on a solid run to $16 from Monday to Friday!!! Let’s F******* GOOOOO!!! 👀 at the Chart 📈 5th WAVE 🌊 showing $21.89!!!!! 🔥 -575 DATA 📊 (Carl said Oct 26’) -New Partnership -New Molecule -12 Week Data 📊 on Phase II Results All…Ahead of 2026 TMS Conference in 3 days October 22, 2026‼️ 🔥
2 replies
Stocktradesmoon Oct 20, 2:49 AM 0 replies
Stocktradesmoon Oct 20, 2:35 AM
$ABCL 👀🏅🤯😮 WAVE 5 PT $21.69 🔥 Beautiful Chart !!! Nice Consolidation ✅ Huge Buys ✅ Ready for the NEXT LEG UP!!! 🔥
3 replies
Stocktradesmoon Oct 20, 2:30 AM
$ABCL 👀 🚨 There are less than 3 days left to find out‼️. GET in NOW or MISS OUT on an ENORMOUS MOVE to $18-$25!!! It’s going to HAPPEN so FAST!!! 😮 🤯 🚀 💨 The BIG BEAST $ABCL is!! The ENTIRE WORLD is going to hear about it!! Can you imagine how many MILLIONS of People and INSTITUTIONS will be ADDING $ABCL to their Portfolios 💼 💉ABCL635 achieved with just ONE dose: 1) -83% in moderate/severe hot flashes vs Placebo: -33% 2) 5.3 fewer episodes PER DAY vs placebo 3) p&t;0.001 4) No serious adverse events in the first 4 weeks 💵And were talking about a market of approximately 12 MILLION women just in the US, of whom more than 6M are seeking treatment. 🗓️This Thursday 3 Days AWAY, October 22, they will present the Phase 2 12 WEEK Data 📊 at the World 🌎 2026 TMS Conference. 🔥And: JPMorgan initiates coverage of $ABCL with OVERWEIGHT and a price target of $18-$25 👀 Looks like well have a party for a few days. 🎉
3 replies
Stocktradesmoon Oct 20, 2:27 AM
$ABCL $ABCL Get in NOW Pre-Market or Regret Missing OUT!! Read my Posts I have been right almost every time. Major catalyst Event in 3 days, this WEEK 🔥 this Thursday, October 22, 2026 TMS Conference we get the 12 Week Data 📊 on the Impressive Phase II Results!!! We are going to MOON 🚀 to $18-$25!!! Just Watch and SEE!! 👀
2 replies